BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 9253507)

  • 1. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.
    Miyatake S; Martuza RL; Rabkin SD
    Cancer Gene Ther; 1997; 4(4):222-8. PubMed ID: 9253507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
    Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
    J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cationic liposomes conjugation to recombinant adenoviral vectors containing herpes simplex virus thymidine kinase gene followed by ganciclovir treatment reduces viral antigenicity and maintains antitumor activity in mouse experimental glioma models.
    Mizuno M; Ryuke Y; Yoshida J
    Cancer Gene Ther; 2002 Oct; 9(10):825-9. PubMed ID: 12224023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma.
    Moriuchi S; Krisky DM; Marconi PC; Tamura M; Shimizu K; Yoshimine T; Cohen JB; Glorioso JC
    Gene Ther; 2000 Sep; 7(17):1483-90. PubMed ID: 11001368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells.
    Takamiya Y; Short MP; Ezzeddine ZD; Moolten FL; Breakefield XO; Martuza RL
    J Neurosci Res; 1992 Nov; 33(3):493-503. PubMed ID: 1335091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir.
    Valerie K; Brust D; Farnsworth J; Amir C; Taher MM; Hershey C; Feden J
    Cancer Gene Ther; 2000 Jun; 7(6):879-84. PubMed ID: 10880018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: consequences for anti-cancer gene therapy.
    Hoshi M; Harada A; Kawase T; Uyemura K; Yazaki T
    Cancer Gene Ther; 2000 May; 7(5):799-805. PubMed ID: 10830727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
    Wildner O; Morris JC
    Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene.
    Ezzeddine ZD; Martuza RL; Platika D; Short MP; Malick A; Choi B; Breakefield XO
    New Biol; 1991 Jun; 3(6):608-14. PubMed ID: 1655012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions.
    Sandmair AM; Turunen M; Tyynelä K; Loimas S; Vainio P; Vanninen R; Vapalahti M; Bjerkvig R; Jänne J; Ylä-Herttuala S
    Cancer Gene Ther; 2000 Mar; 7(3):413-21. PubMed ID: 10766347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase.
    Moriuchi S; Oligino T; Krisky D; Marconi P; Fink D; Cohen J; Glorioso JC
    Cancer Res; 1998 Dec; 58(24):5731-7. PubMed ID: 9865731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitization of rat glioma with bromodeoxycytidine and adenovirus expressing herpes simplex virus-thymidine kinase delivered by slow, rate-controlled positive pressure infusion.
    Brust D; Feden J; Farnsworth J; Amir C; Broaddus WC; Valerie K
    Cancer Gene Ther; 2000 May; 7(5):778-88. PubMed ID: 10830725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir.
    Howard BD; Boenicke L; Schniewind B; Henne-Bruns D; Kalthoff H
    Cancer Gene Ther; 2000 Jun; 7(6):927-38. PubMed ID: 10880025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model.
    Moriuchi S; Wolfe D; Tamura M; Yoshimine T; Miura F; Cohen JB; Glorioso JC
    Gene Ther; 2002 May; 9(9):584-91. PubMed ID: 11973634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy.
    Okada H; Attanucci J; Tahara H; Pollack IF; Bozik ME; Chambers WH; Lotze MT
    Cancer Gene Ther; 2000 Mar; 7(3):486-94. PubMed ID: 10766355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine.
    Toda M; Martuza RL; Rabkin SD
    Gene Ther; 2001 Feb; 8(4):332-9. PubMed ID: 11313808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas.
    Herrlinger U; Woiciechowski C; Sena-Esteves M; Aboody KS; Jacobs AH; Rainov NG; Snyder EY; Breakefield XO
    Mol Ther; 2000 Apr; 1(4):347-57. PubMed ID: 10933953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells.
    Burrows FJ; Gore M; Smiley WR; Kanemitsu MY; Jolly DJ; Read SB; Nicholas T; Kruse CA
    Cancer Gene Ther; 2002 Jan; 9(1):87-95. PubMed ID: 11916247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.